公开(公告)号：US20220378722A1

公开(公告)日：2022-12-01

申请号：US17661971

申请日：2022-05-04

Applicant: Oryzon Genomics, S.A.

Inventor： Mark D. DEMARIO ,  Tamara MAES ,  William E. PIERCEALL ,  Fiona MACK ,  Serena LUNARDI

IPC: A61K31/135 ,  A61K31/12 ,  A61K31/19 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/167 ,  A61K31/404 ,  A61K31/4402 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/635

Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

公开(公告)号：US20190256930A1

公开(公告)日：2019-08-22

申请号：US16346915

申请日：2017-11-02

Applicant: ORYZON GENOMICS, S.A.

Inventor： Maria Isabel ARÉVALO SÁNCHEZ ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT

IPC: C12Q1/6886 ,  A61P35/02 ,  A61K31/135

Abstract: The present invention relates to methods for monitoring the response to treatment with an LSD1 inhibitor in a subject suffering from leukemia. The present invention also provides methods for the identification of a responding subject to treatment with an LSD1 inhibitor. Also methods of determining whether a proliferative diseased cell is responsive to treatment with an LSD1 inhibitor are provided. The methods comprise determining the level of one or more of markers in a sample, wherein an increased level of one or more of said markers compared to a control indicates responsiveness to the LSD1 inhibitor. Methods of treatment of patients with the LSD1 inhibitor, wherein the patients are identified in accordance with the present invention to be responders are also subject of the present invention. LSD1 inhibitors for use in the treatment of this patient group are provided.

公开(公告)号：US20220331265A1

公开(公告)日：2022-10-20

申请号：US17531370

申请日：2021-11-19

Applicant: Oryzon Genomics S.A.

Inventor： Filippo CICERI ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Inigo TIRAPU FERNANDEZ DE LA CUESTA

IPC: A61K31/015 ,  A61K31/12 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/19 ,  A61P35/00 ,  A61K31/135 ,  A61K31/17 ,  A61K31/203 ,  A61K31/496 ,  A61K33/36 ,  A61P35/02 ,  A61K31/64

Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients (I), pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

公开(公告)号：US20190083417A1

公开(公告)日：2019-03-21

申请号：US16084683

申请日：2017-03-13

Applicant: Oryzon Genomics S.A.

Inventor： Filippo CICERI ,  Serena LUNARDI ,  Tamara MAES ,  Cristina MASCARO CRUSAT ,  Inigo TIRAPU FERNANDEZ DE LA CUEST

IPC: A61K31/015 ,  A61K31/12 ,  A61P35/02 ,  A61K31/135 ,  A61K31/17 ,  A61K31/203 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/496 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/36 ,  A61K31/64

Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.